Anavex Life Sciences Corp (AVXL)

[falconer66a]

The economic forces of Blackrock vs health insurance.

Larry Fink's Blackrock controls over $10 Trillion of the market and is a major controlling investor in most of the effective Pharmas and Biotechs.

But can Blackrock’s control of $10 trillion worth of equities prevent Anavex from gaining major market shares for the treatment of CNS diseases outside of the US? If (or when) blarcamesine is proven to effectively treat or prevent Alzheimer’s, what’s the likelihood that the drug will be approved in any of the rest of the world? Australia? The European Union? Canada? Might the Japanese and Koreans wish to have blarcamesine available?

Then, there are the economic considerations of both public and private health insurance entities. Health insurance payments to maintain an Alzheimer’s patient while she slowly progresses toward death are massive; far more than they would be with the treatment or prevention costs of blarcamesine therapy. With blarcamesine, health insurance entities can be profitable; avoiding trillions of dollars of costs for CNS patients.